The company has received tentative approval from the United States Food and Drug Administration for its abbreviated new drug application for Tenofovir Alafenamide tablets
The acquisition will strengthen the company's India formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements, and neurological products.
The approval granted by the US Food and Drug Administration is for the abbreviated new drug application Desvenlafaxine extended-release tablets of strength 25 mg, the company said in a regulatory filing.
The Mumbai-based company's product is the generic version of Viatris Specialty LLC's Revatio
The Mumbai-based drug maker has launched the product in the US market under exclusive license, marketing and distribution agreement with Slayback Pharma LLC